Anti-Human Abeta Recombinant Antibody (Solanezumab) (CAT#: TAB-228)

Recombinant monoclonal antibody to Abeta. It binds to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 shows the mean change over the course of 18 months of treatment with solanezumab or placebo for cognitive and functional outcomes.

Figure 1 shows the mean change over the course of 18 months of treatment with solanezumab or placebo for cognitive and functional outcomes.

For the ADAS-Cog14, as well as the ADAS-Cog11, significant differences between treatment groups were first observed at week 40 and were sustained through endpoint (week 80). For MMSE, the difference between treatment groups reached significance at endpoint. For the ADCS-iADL, significant differences between treatment groups were observed at week 64 and sustained through endpoint. No differences were evident between treatment groups for change from baseline on the ADCS-ADL, the ADCS-bADL subscale or the CDR-SB. The placebo versus active treatment group differences in the ADAS-Cog14 and ADCS-iADL increased over 18 months.

Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., ... & Demattos, R. (2016). Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimer's & Dementia, 12(2), 110-120.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • WB, FuncS, IF, Neut, ELISA, FC, IP
  • CAS
  • 955085-14-0
  • Generic Name
  • Solanezumab
  • UNII
  • 5D6PWO0333
  • MW
  • 144.1 kDa
  • Related Disease
  • Alzheimer's disease (AD)

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The APP antibody has been reported in applications of FuncS.

Target

  • Alternative Names
  • Solanezumab;955085-14-0;LY2062430;m266;10D5;APP;amyloid beta (A4) precursor protein;AD1, Alzheimer disease;amyloid beta A4 protein;peptidase nexin II;preA4;protease nexin-II;peptidase nexin-II;beta-amyloid peptide;alzheimer disease amyloid protein;cerebra

Related Resources

  • Biosimilar Overview
Please refer to Solanezumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Solanezumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Solanezumab"

Afuco™ Anti-APP ADCC Recombinant Antibody (Solanezumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Abeta. It binds to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease.

See other products for "APP"

Recombinant Antibody

CAT Product Name Application Type
PABL-010 Mouse Anti-APP Recombinant Antibody (clone 12A11) WB, IF, FuncS Mouse IgG2a, κ
PABL-011 Mouse Anti-APP Recombinant Antibody (clone 3D6) WB, ELISA, FuncS Mouse IgG1
PABL-012 Human Anti-APP Recombinant Antibody (clone 9TL) WB, FuncS Human IgG2, κ
PABL-013 Mouse Anti-APP Recombinant Antibody (clone C705) WB, ELISA, FuncS Mouse IgG
HPAB-0116CQ Mouse Anti-APP Recombinant Antibody (HPAB-0116CQ) ELISA, WB, IP, FuncS Mouse IgG1, κ

Single-domain Antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0685MZ Chicken Anti-APP Polyclonal IgY IHC Chicken antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-225 Afuco™ Anti-APP ADCC Recombinant Antibody (Bapineuzumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-228 Afuco™ Anti-APP ADCC Recombinant Antibody (Solanezumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-229 Afuco™ Anti-APP ADCC Recombinant Antibody (Gantenerumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-227 Afuco™ Anti-APP ADCC Recombinant Antibody (Ponezumab), ADCC Enhanced ELISA, IP, FC, FuncS, Neut ADCC enhanced antibody
AFC-TAB-226 Afuco™ Anti-APP ADCC Recombinant Antibody (Crenezumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-228. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare